Table 1 Participant characteristics
Overall (n = 30), median (range) or n (%) | Cabozantinib + nivolumab (n = 10), median (range) or n (%) | Cabozantinib + nivolumab + CBM588 (n = 20), median (range) or n (%) | P value | |
---|---|---|---|---|
Age (years) | 65 (36–84) | 60 (48–67) | 68 (36–84) | 0.237 |
Gender | ||||
Male | 20 (67) | 5 (50) | 15 (75) | 0.230 |
Female | 10 (33) | 5 (50) | 5 (25) | |
Race | ||||
White | 26 (87) | 7 (70) | 19 (95) | 0.563 |
Asian | 3 (10) | 2 (20) | 1 (5) | |
Other | 1 (3) | 1 (10) | 0 (0) | |
Ethnicity | ||||
Non-Hispanic or non-Latinx | 15 (50) | 4 (40) | 11 (55) | 0.699 |
Hispanic or Latinx | 15 (50) | 6 (60) | 9 (45) | |
Histologic subtype | ||||
Clear cell | 26 (87) | 8 (80) | 18 (90) | 0.584 |
Clear cell with sarcomatoid features | 3 (10) | 1 (10) | 2 (10) | |
Papillary | 2 (7) | 0 (0) | 2 (10) | |
Sarcomatoid dedifferentiation | 2 (7) | 2 (20) | 0 (0) | |
IMDC prognostic risk | ||||
Favorable | 12 (40) | 3 (30) | 9 (45) | 0.070 |
Intermediate | 12 (40) | 5 (50) | 7 (35) | |
Poor | 6 (20) | 2 (20) | 4 (20) | |
Nephrectomy | ||||
Yes | 20 (67) | 6 (60) | 14 (70) | 0.690 |
No | 10 (33) | 4 (40) | 6 (30) | |
Number of metastatic sites | ||||
≥2 | 24 (80) | 8 (80) | 16 (80) | 1.000 |
Most common metastatic sites | ||||
Lung | 24 (80) | 8 (80) | 16 (80) | 1.000 |
Lymph node | 15 (50) | 6 (60) | 9 (45) | 0.699 |
Bone | 12 (40) | 4 (40) | 8 (40) | 1.000 |
Adrenal | 5 (17) | 0 (0) | 5 (25) | 0.140 |
Liver | 3 (10) | 2 (20) | 1 (5) | 0.251 |
Pancreas | 1 (3) | 1 (10) | 0 (0) | 0.333 |